Evidence map›Paper›PMID 26692492›Full record

ArticleBiochemical and biophysical research communications2016

Nanoformulated copper/zinc superoxide dismutase attenuates vascular cell activation and aortic inflammation in obesity.

Viswanathan Saraswathi, Murali Ganesan, Curtis Perriotte-Olson, Devika S Manickam, Rachel A Westwood, Matthew C Zimmerman, Iman M Ahmad, Cyrus V Desouza, Alexander V Kabanov

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Targeted Nano-Based Systems for the Anti-Obesity Agent's Delivery.Advances in experimental medicine and biology · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Enzymes as Immunotherapeutics.Bioconjugate chemistry · 2018
    Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Viswanathan SaraswathiDepartment of Internal Medicine/Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA; Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, USA; VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA. Electronic address: s.viswanathan@unmc.edu.
Murali GanesanDepartment of Internal Medicine/Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA; VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Curtis Perriotte-OlsonDepartment of Internal Medicine/Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA; VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Devika S ManickamDivision of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Rachel A WestwoodDepartment of Internal Medicine/Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA; VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
Matthew C ZimmermanDepartment of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, USA.
Iman M AhmadRadiation Science Technology Education, College of Allied Health Professions, University of Nebraska Medical Center, Omaha, USA.
Cyrus V DesouzaVA Nebraska-Western Iowa Health Care System, Omaha, NE, USA; Department of Internal Medicine/Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA.
Alexander V KabanovDivision of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
University of Nebraska Medical Center · USUniversity of North Carolina at Chapel Hill · USNebraska Medical Center · US

Funding

Project 9 - Renal Drug Targeting for the Treatment of Lupus NephritisP20GM103480 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRONICH, TATIANA K · 2012 to 2017
$13.3M
NIGMS NIH HHS 2P20GM103480NIGMS NIH HHS P20 GM103480
6 · The paper itself

Abstract

objectiveEndothelial cell (EC) oxidative stress can lead to vascular dysfunction which is an underlying event in the development of cardiovascular disease (CVD). The lack of a potent and bioavailable anti-oxidant enzyme is a major challenge in studies on antioxidant therapy. The objective of this study is to determine whether copper/zinc superoxide dismutase (CuZnSOD or SOD1) after nanoformulation (nanoSOD) can effectively reduce EC oxidative stress and/or vascular inflammation in obesity.

methodsHuman aortic endothelial cells (HAECs) were treated with native- or nanoSOD for 6 h followed by treatment with linoleic acid (LA), a free fatty acid, for 6-24 h. To determine the in vivo relevance, the effectiveness of nanoSOD in reducing vascular cell activation was studied in a mouse model of diet-induced obesity.

resultsWe noted that nanoSOD was more effectively taken up by ECs than native SOD. Western blot analysis further confirmed that the intracellular accumulation of SOD1 protein was greatly increased upon nanoSOD treatment. Importantly, nanoSOD pretreatment led to a significant decrease in LA-induced oxidative stress in ECs which was associated with a marked increase in SOD enzyme activity in ECs. In vivo studies showed a significant decrease in markers of EC/vascular cell activation and/or inflammation in visceral adipose tissue (VAT), thoracic aorta, and heart collected from nanoSOD-treated mice compared to obese control mice. Interestingly, the expression of metallothionein 2, an antioxidant gene was significantly increased in nanoSOD-treated mice.

conclusionOur data show that nanoSOD is very effective in delivering active SOD to ECs and in reducing EC oxidative stress. Our data also demonstrate that nanoSOD will be a useful tool to reduce vascular cell activation in VAT and aorta in obesity which, in turn, can protect against obesity-associated CVD, in particular, hypertension.

Indexed as

AnimalsAortitisCells, CulturedDrug CompoundingEndothelial CellsFree Radical ScavengersHumansMiceMice, Inbred C57BLNanocapsulesObesitySuperoxide DismutaseTreatment OutcomeFree Radical ScavengersNanocapsulesSuperoxide DismutaseFree fatty acidNanoSODObesityOxidative stressSuperoxide dismutaseVascular inflammation

Identifiers

PMID26692492
PMCPMC6368064
OpenAlexW2195710065

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.